Sarepta Therapeutics (NASDAQ: SRPT) announced the Peripheral and Central Nervous System Drugs Advisory Committee of the U.S. Food and Drug ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Roth Capital Reiterates Buy on Sarepta Therapeutics (SRPT) as Advisory Meeting Set for January 22nd October 15, 2015 9:52 AM AdCom Changes Gives Sarepta Therapeutic (SRPT) Prep Time; Recommends Owning Into Briefing Doc ReleaseOctober 15, 2015 8:00 AM Sarepta Therapeutics Announces Tentative FDA Advisory Committee Meeting to Review Eteplirsen as a Treatment for Duchenne Muscular DystrophyOctober 14, 2015 12:43 PM Sarepta Therapeutics' (SRPT) Eteplirsen May Be Reviewed on Jan. 22 by FDA Panel - BloombergOctober 14, 2015 11:43 AM Sarepta's (SRPT) DMD drug may be reviewed by FDA panel in January - BloombergOctober 14, 2015 11:41 AM BioMarin's (BMRN) Drisparsen Advisory Committee Meeting Set for Nov. 24 October 14, 2015 9:16 AM